Serious fungal infections are becoming increasingly drug resistant, creating an urgent need for new treatment options. SCYNEXIS is advancing a differentiated class of triterpenoid antifungals designed to address difficult-to-treat infections, with a growing pipeline spanning multiple generations and potential indications.
Drug-resistant fungal infections are an increasing global threat. Pathogens such as Candida auris, drug-resistant Aspergillus, and Mucorales can cause severe, often life-threatening infections with limited treatment options. There is an urgent need for new antifungal therapies, and SCYNEXIS’ proprietary triterpenoid platform has the potential to address these challenges through a novel glucan synthase inhibition approach with oral and IV treatment options.
Invasive fungal infections can be life-threatening, particularly in vulnerable patients. Explore the diseases and pathogens driving the need for new, effective antifungal therapies.
Invasive fungal infections kill more than one million people in hospitals each year worldwide. The significant burden of disease underscores the importance of effective prophylactic therapies, which have the potential to reduce both patient mortality and healthcare costs by preventing infections before they develop.
Invasive candidiasis is a serious fungal infection caused by various Candida species and occurs most frequently in immunocompromised patients. Overall mortality in patients with invasive candidiasis and candidemia is reported ~40%.
Discover the clinical evidence, ongoing trials, and pipeline programs driving our work to advance new solutions for serious and difficult-to-treat fungal infection